ATE224364T1 - Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren - Google Patents

Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren

Info

Publication number: ATE224364T1
Authority: AT; Austria
Prior art keywords: beta; hydroxamic acid; matrix metalloproteinase; tace inhibitors; sulfonamido
Prior art date: 1996-10-16

Application number

AT97912674T

Other languages

English (en)

Inventor

Jeremy Ian Levin

Arie Zask

Yansong Gu

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-16

Filing date

1997-10-08

Publication date

2002-10-15

1997-10-08 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE224364T1 publication Critical patent/ATE224364T1/de

Links

NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
239000002253 acid Substances 0.000 title 1
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT97912674T 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren ATE224364T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72935996A	1996-10-16	1996-10-16
PCT/US1997/018170 WO1998016506A1 (en)	1996-10-16	1997-10-08	Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (1)

Publication Number	Publication Date
ATE224364T1 true ATE224364T1 (de)	2002-10-15

Family

ID=24930685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97912674T ATE224364T1 (de)	1996-10-16	1997-10-08	Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren

Country Status (17)

Country	Link
EP (1)	EP0934259B1 (de)
JP (1)	JP2001502326A (de)
KR (1)	KR20000049198A (de)
CN (1)	CN1105101C (de)
AR (1)	AR008676A1 (de)
AT (1)	ATE224364T1 (de)
AU (1)	AU736134B2 (de)
BR (1)	BR9712524A (de)
CA (1)	CA2268895A1 (de)
DE (1)	DE69715647T2 (de)
DK (1)	DK0934259T3 (de)
ES (1)	ES2184069T3 (de)
IL (1)	IL129149A (de)
NZ (1)	NZ335053A (de)
PT (1)	PT934259E (de)
WO (1)	WO1998016506A1 (de)
ZA (1)	ZA979236B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0952148B1 (de) *	1998-04-10	2004-05-12	Pfizer Products Inc.	Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
CA2333554A1 (en)	1998-06-17	1999-12-23	Chu-Baio Xue	Cyclic hydroxamic acids as metalloproteinase inhibitors
US6358980B1 (en)	1999-01-27	2002-03-19	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AU2320500A (en) *	1999-02-02	2000-08-25	Shionogi & Co., Ltd.	Sulfonamide derivatives having cyclic structures
ATE384756T1 (de) *	2000-05-23	2008-02-15	Ge Osmonics Inc	Modifizierte sulfonamidpolymere
BR0213736A (pt)	2001-11-01	2004-10-19	Wyeth Corp	ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
US7491718B2 (en)	2002-10-08	2009-02-17	Abbott Laboratories	Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) *	2002-10-08	2004-08-12	Comess Kenneth M.	Sulfonamides having antiangiogenic and anticancer activity
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2005092844A1 (en) *	2004-03-22	2005-10-06	Southern Research Institute	Nonpeptide inhibitors of matrix metalloproteinases
FR2947270B1 (fr) *	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en)	2013-03-15	2014-09-18	Galderma Research & Development	Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en)	2015-03-19	2016-03-24	Yeda Res & Dev	Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en)	2015-12-28	2017-07-06	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (es)	2016-02-01	2019-01-08	Galderma Res & Dev	Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
CN113194954A (zh)	2018-10-04	2021-07-30	国家医疗保健研究所	用于治疗角皮病的egfr抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
CA2160139A1 (en) *	1993-04-07	1994-10-13	Richard Edward Galardy	Synthetic matrix metalloprotease inhibitors and uses thereof
US5672598A (en) *	1995-03-21	1997-09-30	The Procter & Gamble Company	Lactam-containing hydroxamic acids

1997
- 1997-10-08 AU AU49790/97A patent/AU736134B2/en not_active Ceased
- 1997-10-08 WO PCT/US1997/018170 patent/WO1998016506A1/en not_active Ceased
- 1997-10-08 DK DK97912674T patent/DK0934259T3/da active
- 1997-10-08 IL IL12914997A patent/IL129149A/xx not_active IP Right Cessation
- 1997-10-08 CA CA002268895A patent/CA2268895A1/en not_active Abandoned
- 1997-10-08 NZ NZ335053A patent/NZ335053A/xx unknown
- 1997-10-08 EP EP97912674A patent/EP0934259B1/de not_active Expired - Lifetime
- 1997-10-08 BR BR9712524-5A patent/BR9712524A/pt not_active Application Discontinuation
- 1997-10-08 ES ES97912674T patent/ES2184069T3/es not_active Expired - Lifetime
- 1997-10-08 DE DE69715647T patent/DE69715647T2/de not_active Expired - Fee Related
- 1997-10-08 JP JP10518424A patent/JP2001502326A/ja not_active Ceased
- 1997-10-08 PT PT97912674T patent/PT934259E/pt unknown
- 1997-10-08 CN CN97180606A patent/CN1105101C/zh not_active Expired - Fee Related
- 1997-10-08 AT AT97912674T patent/ATE224364T1/de not_active IP Right Cessation
- 1997-10-08 KR KR1019990703296A patent/KR20000049198A/ko not_active Abandoned
- 1997-10-15 AR ARP970104748A patent/AR008676A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA9709236A patent/ZA979236B/xx unknown

Also Published As

Publication number	Publication date
IL129149A (en)	2003-10-31
DE69715647D1 (en)	2002-10-24
DK0934259T3 (da)	2003-01-27
ZA979236B (en)	1999-07-15
AR008676A1 (es)	2000-02-09
WO1998016506A1 (en)	1998-04-23
NZ335053A (en)	2000-10-27
AU4979097A (en)	1998-05-11
ES2184069T3 (es)	2003-04-01
EP0934259B1 (de)	2002-09-18
CN1240424A (zh)	2000-01-05
BR9712524A (pt)	1999-10-19
EP0934259A1 (de)	1999-08-11
DE69715647T2 (de)	2003-02-20
PT934259E (pt)	2003-01-31
AU736134B2 (en)	2001-07-26
KR20000049198A (ko)	2000-07-25
HK1020720A1 (en)	2000-05-19
CA2268895A1 (en)	1998-04-23
CN1105101C (zh)	2003-04-09
IL129149A0 (en)	2000-02-17
JP2001502326A (ja)	2001-02-20

Legal Events

Date	Code	Title
2003-01-15	UEP	Publication of translation of european patent specification
2003-11-15	EEFA	Change of the company name
2007-07-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE224364T1 (de)	2002-10-15	Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren
ATE257151T1 (de)	2004-01-15	Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
FI965156A7 (fi)	1996-12-20	Aryylisulfonamido-substituoidut hydroksaamihapot matriisimetalloprotei naasi-inhibiittoreina
DK0938471T3 (da)	2002-01-28	Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
ATE219058T1 (de)	2002-06-15	Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase- inhibitoren
BR9510175A (pt)	1997-10-14	Inibidores contendo ácido hidroxâmico de metaloproteases de matriz
NO972307D0 (no)	1997-05-21	Matriksmetallproteaseinhibitorer
FI962904A7 (fi)	1996-07-19	Metalloproteinaasi-inhibiittoreita
FI962905L (fi)	1996-07-19	Metalloproteinaasi-inhibiittoreita
FI954351A7 (fi)	1995-09-15	Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
IL129148A0 (en)	2000-02-17	The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
ATE226590T1 (de)	2002-11-15	Phosphinsäureamide als matrix metalloprotease inhibitoren
NO991922L (no)	1999-04-22	Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
DK0977733T3 (da)	2003-11-24	Arylsulfonylaminohydroxamsyrederivater
FI960482A7 (fi)	1996-02-02	Matriksin metalloproteaasien inhibiittorit
FI972198L (fi)	1997-05-23	Metalloproteinaasi-inhibiittoreita
ATE260251T1 (de)	2004-03-15	Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren
GB9613547D0 (en)	1996-08-28	Matrix metalloproteinase inhibitors
DE60012303D1 (de)	2004-08-26	Alkinylische hydroxamsäureverbindungen als tace inhibitoren
HUP0100564A3 (en)	2003-07-28	Matrix metalloproteinase inhibitors and pharmaceuticals comprising them
BR9707024A (pt)	1999-07-20	Inibidores de colagenase com base em ácido hidroxâmico
ATE227288T1 (de)	2002-11-15	Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren
DK0929517T3 (da)	2002-10-07	Hydroxamsyrederivater
GB9702085D0 (en)	1997-03-19	Matrix metalloproteinase inhibitors
ATE228999T1 (de)	2002-12-15	Metalloproteinaseinhibitoren